These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30277131)

  • 21. Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma.
    Miyagaki T; Sugaya M; Suga H; Morimura S; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    J Invest Dermatol; 2012 Apr; 132(4):1280-9. PubMed ID: 22297640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
    Kato Y; Egusa C; Maeda T; Tsuboi R
    J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The retinoid derivant ECPIRM selectively exhibited anti-proliferation effects in cutaneous T-Cell lymphoma via ITK-mediated signaling pathway.
    Li H; Wang C; Ma P; Zhang M; Yang H; Yuan S; Wei J; Tao L; Qian K; Xu M; Li L
    J Dermatol Sci; 2020 Mar; 97(3):208-215. PubMed ID: 32165081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased HMGB1 levels in lesional skin and sera in patients with cutaneous T-cell lymphoma.
    Senda N; Miyagaki T; Kamijo H; Nakajima R; Oka T; Takahashi N; Suga H; Yoshizaki A; Asano Y; Sugaya M; Sato S
    Eur J Dermatol; 2018 Oct; 28(5):621-627. PubMed ID: 30378541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma.
    Yamanaka K; Clark R; Rich B; Dowgiert R; Hirahara K; Hurwitz D; Shibata M; Mirchandani N; Jones DA; Goddard DS; Eapen S; Mizutani H; Kupper TS
    Blood; 2006 Mar; 107(6):2440-5. PubMed ID: 16322477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages.
    Linde N; Lederle W; Depner S; van Rooijen N; Gutschalk CM; Mueller MM
    J Pathol; 2012 May; 227(1):17-28. PubMed ID: 22262122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.
    Kohnken R; McNeil B; Wen J; McConnell K; Grinshpun L; Keiter A; Chen L; William B; Porcu P; Mishra A
    J Invest Dermatol; 2019 Sep; 139(9):1966-1974.e3. PubMed ID: 30876800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-25 is involved in cutaneous T-cell lymphoma progression by establishing a T helper 2-dominant microenvironment.
    Nakajima R; Miyagaki T; Hirakawa M; Oka T; Takahashi N; Suga H; Yoshizaki A; Fujita H; Asano Y; Sugaya M; Sato S
    Br J Dermatol; 2018 Jun; 178(6):1373-1382. PubMed ID: 29238954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover.
    Krejsgaard T; Lindahl LM; Mongan NP; Wasik MA; Litvinov IV; Iversen L; Langhoff E; Woetmann A; Odum N
    Semin Immunopathol; 2017 Apr; 39(3):269-282. PubMed ID: 27717961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ontak-like human IL-2 fusion toxin.
    Wang Z; Zheng Q; Zhang H; Bronson RT; Madsen JC; Sachs DH; Huang CA; Wang Z
    J Immunol Methods; 2017 Sep; 448():51-58. PubMed ID: 28551309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-cell RNA sequencing unveils the communications between malignant T and myeloid cells contributing to tumor growth and immunosuppression in cutaneous T-cell lymphoma.
    Du Y; Cai Y; Lv Y; Zhang L; Yang H; Liu Q; Hong M; Teng Y; Tang W; Ma R; Wu J; Wu J; Wang Q; Chen H; Li K; Feng J
    Cancer Lett; 2022 Dec; 551():215972. PubMed ID: 36265653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma.
    Nakajima R; Miyagaki T; Kamijo H; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S
    J Dermatol Sci; 2019 Dec; 96(3):134-142. PubMed ID: 31787505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma.
    Matsuda Y; Ikeda S; Abe F; Takahashi Y; Kitadate A; Takahashi N; Wakui H; Tagawa H
    Cancer Sci; 2022 Apr; 113(4):1208-1219. PubMed ID: 35133054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.
    Jain S; Washington A; Leaf RK; Bhargava P; Clark RA; Kupper TS; Stroopinsky D; Pyzer A; Cole L; Nahas M; Apel A; Rosenblatt J; Arnason J; Kufe D; Avigan D
    Mol Cancer Ther; 2017 Oct; 16(10):2304-2314. PubMed ID: 28729399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells.
    Marzec M; Halasa K; Kasprzycka M; Wysocka M; Liu X; Tobias JW; Baldwin D; Zhang Q; Odum N; Rook AH; Wasik MA
    Cancer Res; 2008 Feb; 68(4):1083-91. PubMed ID: 18281483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous manifestations of Epstein-Barr virus-associated T-cell lymphoma.
    Su IJ; Tsai TF; Cheng AL; Chen CC
    J Am Acad Dermatol; 1993 Nov; 29(5 Pt 1):685-92. PubMed ID: 8227539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
    Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
    Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel xenograft model of cutaneous T-cell lymphoma.
    Krejsgaard T; Kopp K; Ralfkiaer E; Willumsgaard AE; Eriksen KW; Labuda T; Rasmussen S; Mathiesen AM; Geisler C; Lauenborg B; Becker JC; Zhang Q; Wasik MA; Odum N; Woetmann A
    Exp Dermatol; 2010 Dec; 19(12):1096-102. PubMed ID: 20629733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.